Aron Goldhirsch
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer
Pagani O, Winer E, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price K, Bernhard J, Luo W, Ribi K, Viale G, Coates A, Gelber R, Goldhirsch A, Francis P, TEXT and SOFT Investigators, Ruhstaller T, Crivellari D, Puglisi F, Regan M, Walley B, Fleming G, Colleoni M, Láng I, Gomez H, Tondini C, Burstein H, Perez E, Ciruelos E, Stearns V, Bonnefoi H, Martino S, Geyer C, Pinotti G, International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371:107-18.
01.06.2014Adjuvant exemestane with ovarian suppression in premenopausal breast cancer
01.06.2014N Engl J Med 2014; 371:107-18
Pagani Olivia, Winer Eric P, Rabaglio-Poretti Manuela, Maibach Rudolf, Ruepp Barbara, Giobbie-Hurder Anita, Price Karen N, Bernhard Jürg, Luo Weixiu, Ribi Karin, Viale Giuseppe, Coates Alan S, Gelber Richard D, Goldhirsch Aron, Francis Prudence A, TEXT and SOFT Investigators, Ruhstaller Thomas, Crivellari Diana, Puglisi Fabio, Regan Meredith M, Walley Barbara A, Fleming Gini F, Colleoni Marco, Láng István, Gomez Henry L, Tondini Carlo, Burstein Harold J, Perez Edith A, Ciruelos Eva, Stearns Vered, Bonnefoi Hervé R, Martino Silvana, Geyer Charles E, Pinotti Graziella, International Breast Cancer Study Group
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
Decensi A, Coates A, Goldhirsch A, Gelber R, Price K, Johansson H, Zaman K, Schönenberger A, Debled M, Campone M, Monnier A, Tondini C, McIntosh C, Thürlimann B, Guerrieri-Gonzaga A, Sun Z, Aebi S. Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. Breast Cancer Res Treat 2014; 144:321-9.
01.02.2014Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
01.02.2014Breast Cancer Res Treat 2014; 144:321-9
Decensi Andrea, Coates Alan S, Goldhirsch Aron, Gelber Richard D, Price Karen N, Johansson Harriet, Zaman Khalil, Schönenberger Astrid, Debled Marc, Campone Mario, Monnier Alain, Tondini Carlo, McIntosh Christina, Thürlimann Beat, Guerrieri-Gonzaga Aliana, Sun Zhuoxin, Aebi Stefan
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial
Ewertz M, Goldhirsch A, Coates A, Smith I, Láng I, Colleoni M, Gelber R, Rabaglio M, Paridaens R, Forbes J, Bonnefoi H, Thürlimann B, Price K, Ejlertsen B, Regan M, Gray K, Mouridsen H. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol 2012; 30:3967-75.
08.10.2012Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial
08.10.2012J Clin Oncol 2012; 30:3967-75
Ewertz Marianne, Goldhirsch Aron, Coates Alan S, Smith Ian E, Láng István, Colleoni Marco, Gelber Richard D, Rabaglio Manuela, Paridaens Robert J, Forbes John F, Bonnefoi Hervé, Thürlimann Beat, Price Karen N, Ejlertsen Bent, Regan Meredith M, Gray Kathryn P, Mouridsen Henning T
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial
Regan M, Debled M, Maibach R, Price K, Gelber R, Coates A, Goldhirsch A, Rae J, Viale G, Neven P, Ditzel H, Lyng M, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'Orto P, Biasi M, Thürlimann B, Breast International Group (BIG) 1-98 Collaborative Group. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 2012; 104:441-51.
06.03.2012CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial
06.03.2012J Natl Cancer Inst 2012; 104:441-51
Regan Meredith M, Debled Marc, Maibach Rudolf, Price Karen N, Gelber Richard D, Coates Alan S, Goldhirsch Aron, Rae James M, Viale Giuseppe, Neven Patrick, Ditzel Henrik J, Lyng Maria B, Leyland-Jones Brian, Bouzyk Mark, Pagani Olivia, Tang Weining, Kammler Roswitha, Dell'Orto Patrizia, Biasi Maria Olivia, Thürlimann Beat, Breast International Group (BIG) 1-98 Collaborative Group
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
Regan M, BIG 1-98 Collaborative Group, Thürlimann B, Coates A, Gelber R, Price K, Rabaglio M, Wardley A, Láng I, Smith I, Forbes J, Mauriac L, Ejlertsen B, Goldhirsch A, Giobbie-Hurder A, Neven P, International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol 2011; 12:1101-8.
20.10.2011Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
20.10.2011Lancet Oncol 2011; 12:1101-8
Regan Meredith M, BIG 1-98 Collaborative Group, Thürlimann Beat, Coates Alan S, Gelber Richard D, Price Karen N, Rabaglio Manuela, Wardley Andrew, Láng István, Smith Ian, Forbes John F, Mauriac Louis, Ejlertsen Bent, Goldhirsch Aron, Giobbie-Hurder Anita, Neven Patrick, International Breast Cancer Study Group (IBCSG)
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause
Chirgwin J, Coates A, Goldhirsch A, Regan M, Bonnefoi H, Ejlertsen B, Thürlimann B, Price K, Smith I, Sun Z, BIG 1-98 Collaborative and International Breast Cancer Study Groups. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast Cancer Res Treat 2011; 131:295-306.
04.09.2011The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause
04.09.2011Breast Cancer Res Treat 2011; 131:295-306
Chirgwin Jacquie, Coates Alan S, Goldhirsch Aron, Regan Meredith M, Bonnefoi Hervé, Ejlertsen Bent, Thürlimann Beat, Price Karen N, Smith Ian, Sun Zhuoxin, BIG 1-98 Collaborative and International Breast Cancer Study Groups
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
Colleoni M, Coates A, Gelber R, Price K, Wardley A, Pienkowski T, Chirgwin J, Smith I, Láng I, Paridaens R, Forbes J, Mauriac L, Mouridsen H, Thürlimann B, Regan M, Giobbie-Hurder A, Goldhirsch A. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 2011; 29:1117-24.
14.02.2011Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
14.02.2011J Clin Oncol 2011; 29:1117-24
Colleoni Marco, Coates Alan S, Gelber Richard D, Price Karen N, Wardley Andrew, Pienkowski Tadeusz, Chirgwin Jacquie, Smith Ian, Láng István, Paridaens Robert, Forbes John F, Mauriac Louis, Mouridsen Henning, Thürlimann Beat, Regan Meredith M, Giobbie-Hurder Anita, Goldhirsch Aron
Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
Phillips K, Gelber R, Price K, Goldhirsch A, Coates A, Pagani O, Cardoso F, Thürlimann B, Harvey V, Thompson A, Sun Z, Ribi K, Aldridge J, Bernhard J. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat 2010
03.11.2010Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
03.11.2010Breast Cancer Res Treat 2010
Phillips Kelly-Anne, Gelber Richard D, Price Karen N, Goldhirsch Aron, Coates Alan S, Pagani Olivia, Cardoso Fatima, Thürlimann Beat, Harvey Vernon, Thompson Alastair, Sun Zhuoxin, Ribi Karin, Aldridge Julie, Bernhard Jürg
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial
Phillips K, Gelber R, Price K, Goldhirsch A, Coates A, Pagani O, Cardoso F, Thürlimann B, Harvey V, Thompson A, Stephens A, Sun Z, Ribi K, Bernhard J. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast 2010; 19:388-95.
10.04.2010Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial
10.04.2010Breast 2010; 19:388-95
Phillips Kelly-Anne, Gelber Richard D, Price Karen N, Goldhirsch Aron, Coates Alan S, Pagani Olivia, Cardoso Fatima, Thürlimann Beat, Harvey Vernon, Thompson Alastair, Stephens Alisa, Sun Zhuoxin, Ribi Karin, Bernhard Jürg
Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer
Paridaens R, Coates A, Crivellari D, Holmberg S, Price K, Thürlimann B, Gelber R, Cole B, Gelber S, Goldhirsch A. Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 2010; 123:303-10.
27.02.2010Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer
27.02.2010Breast Cancer Res Treat 2010; 123:303-10
Paridaens Robert J, Coates Alan S, Crivellari Diana, Holmberg Stig B, Price Karen N, Thürlimann Beat, Gelber Richard D, Cole Bernard F, Gelber Shari, Goldhirsch Aron
Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century
Pagani O, Goldhirsch A, Coates A, Fey M, Collins J, Thürlimann B, Lindtner J, Holmberg S, Castiglione-Gertsch M, Gelber R, Price K, International Breast Cancer Study Group (IBCSG). Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century. Breast Cancer Res Treat 2009; 117:319-24.
01.09.2009Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century
01.09.2009Breast Cancer Res Treat 2009; 117:319-24
Pagani Olivia, Goldhirsch Aron, Coates Alan S, Fey Martin F, Collins John, Thürlimann Beat, Lindtner Jurij, Holmberg Stig B, Castiglione-Gertsch Monica, Gelber Richard D, Price Karen N, International Breast Cancer Study Group (IBCSG)
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer
BIG 1-98 Collaborative Group, Gelber R, Regan M, Price K, Forbes J, Mauriac L, Smith I, Paridaens R, Thürlimann B, Goldhirsch A, Giobbie-Hurder A, Mouridsen H, Coates A. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. NEJM 2009; 361:766-76.
20.08.2009Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer
20.08.2009NEJM 2009; 361:766-76
BIG 1-98 Collaborative Group, Gelber Richard D, Regan Meredith M, Price Karen N, Forbes John F, Mauriac Louis, Smith Ian, Paridaens Robert, Thürlimann Beat, Goldhirsch Aron, Giobbie-Hurder Anita, Mouridsen Henning, Coates Alan S
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93
Pagani O, Goldhirsch A, Coates A, Forbes J, Murray E, Fey M, Thürlimann B, Lindtner J, Collins J, Crivellari D, Holmberg S, Gelber R, Price K, Castiglione-Gertsch M, Simoncini E, Gelber S, International Breast Cancer Study Group. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat 2009; 116:491-500.
01.08.2009Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93
01.08.2009Breast Cancer Res Treat 2009; 116:491-500
Pagani Olivia, Goldhirsch Aron, Coates Alan S, Forbes John F, Murray Elizabeth, Fey Martin F, Thürlimann Beat, Lindtner Jurij, Collins John, Crivellari Diana, Holmberg Stig B, Gelber Richard D, Price Karen N, Castiglione-Gertsch Monica, Simoncini Edda, Gelber Shari, International Breast Cancer Study Group
Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93
Thürlimann B, Coates A, Castiglione-Gertsch M, Forbes J, Collins J, Colleoni M, Crivellari D, Holmberg S, Gelber R, Price K, Goldhirsch A. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res Treat 2009; 113:137-44.
01.01.2009Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93
01.01.2009Breast Cancer Res Treat 2009; 113:137-44
Thürlimann Beat, Coates Alan S, Castiglione-Gertsch Monica, Forbes John F, Collins John, Colleoni Marco, Crivellari Diana, Holmberg Stig B, Gelber Richard D, Price Karen N, Goldhirsch Aron
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole
Viale G, Olszewski W, Knox F, Thürlimann B, Price K, Castiglione-Gertsch M, Gelber R, Gusterson B, Goldhirsch A, Orosz Z, Neven P, Öhlschlegel C, Giobbie-Hurder A, Regan M, Coates A, Mastropasqua M, Dell'Orto P, Maiorano E, MacGrogan G, Braye S, Breast International Group Trial 1-98. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008; 26:5569-75.
03.11.2008Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole
03.11.2008J Clin Oncol 2008; 26:5569-75
Viale Giuseppe, Olszewski Wojciech P, Knox Fiona, Thürlimann Beat, Price Karen N, Castiglione-Gertsch Monica, Gelber Richard D, Gusterson Barry A, Goldhirsch Aron, Orosz Zsolt, Neven Patrick, Öhlschlegel Christian, Giobbie-Hurder Anita, Regan Meredith M, Coates Alan S, Mastropasqua Mauro G, Dell'Orto Patrizia, Maiorano Eugenio, MacGrogan Gaëtan, Braye Stephen G, Breast International Group Trial 1-98
Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials
Pestalozzi B, Goldhirsch A, Coates A, Castiglione-Gertsch M, Viale G, Murray E, Thürlimann B, Snyder R, Lindtner J, Holmberg S, Gelber R, Price K, Gusterson B, Mallon E, Zahrieh D, International Breast Cancer Study Group. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. JCO 2008; 26:3006-14.
20.06.2008Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials
20.06.2008JCO 2008; 26:3006-14
Pestalozzi Bernhard C, Goldhirsch Aron, Coates Alan S, Castiglione-Gertsch Monica, Viale Giuseppe, Murray Elizabeth, Thürlimann Beat, Snyder Raymond, Lindtner Jurij, Holmberg Stig B, Gelber Richard D, Price Karen N, Gusterson Barry A, Mallon Elizabeth, Zahrieh David, International Breast Cancer Study Group
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial
Crivellari D, Chirgwin J, Smith I, Rabaglio M, Gladieff L, Del Mastro L, Láng I, Colleoni M, Gelber R, Castiglione-Gertsch M, Paridaens R, Forbes J, Mauriac L, Mouridsen H, Thürlimann B, Price K, Coates A, Sun Z, Goldhirsch A. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. JCO 2008; 26:1972-9.
20.04.2008Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial
20.04.2008JCO 2008; 26:1972-9
Crivellari Diana, Chirgwin Jacquie H, Smith Ian E, Rabaglio Manuela, Gladieff Laurence, Del Mastro Lucia, Láng István, Colleoni Marco, Gelber Richard D, Castiglione-Gertsch Monica, Paridaens Robert J, Forbes John F, Mauriac Louis, Mouridsen Henning, Thürlimann Beat, Price Karen N, Coates Alan S, Sun Zhuoxin, Goldhirsch Aron
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group
Viale G, Gusterson B, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Rusca T, Grigolato P, Braye S, Öhlschlegel C, Pillay K, Kovács A, Brown R, Perin T, Golouh R, Mastropasqua M, Maiorano E, Regan M, Coates A. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. J Clin Oncol 2008; 26:1404-10.
20.03.2008Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group
20.03.2008J Clin Oncol 2008; 26:1404-10
Viale Giuseppe, Gusterson Barry A, Goldhirsch Aron, Price Karen N, Castiglione-Gertsch Monica, Gelber Richard D, Rusca Tiziana, Grigolato Piergiovanni, Braye Stephen, Öhlschlegel Christian, Pillay Komala, Kovács Anikó, Brown Robert W, Perin Tiziana, Golouh Rastko, Mastropasqua Mauro G, Maiorano Eugenio, Regan Meredith M, Coates Alan S
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
Viale G, Coates A, Goldhirsch A, Gelber R, Castiglione-Gertsch M, Gusterson B, Öhlschlegel C, Pillay K, Kovács A, Brown R, Perin T, Golouh R, Price K, Colleoni M, Maiorano E, Maffini F, Mastropasqua M, Regan M, International Breast Cancer Study Group. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 2008; 100:207-12.
29.01.2008Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
29.01.2008J Natl Cancer Inst 2008; 100:207-12
Viale Giuseppe, Coates Alan S, Goldhirsch Aron, Gelber Richard D, Castiglione-Gertsch Monica, Gusterson Barry A, Öhlschlegel Christian, Pillay Komala, Kovács Anikó, Brown R W, Perin Tiziana, Golouh Rastko, Price Karen N, Colleoni Marco, Maiorano Eugenio, Maffini Fausto, Mastropasqua Mauro G, Regan Meredith M, International Breast Cancer Study Group
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
Rasmussen B, Altermatt H, Gelber R, Castiglione-Gertsch M, Goldhirsch A, Gusterson B, Thürlimann B, Coates A, Viale G, Braye S, Lacroix-Triki M, Regan M, Lykkesfeldt A, Dell'Orto P, Del Curto B, Henriksen K, Mastropasqua M, Price K, Méry E, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. The Lancet 2008; 9:23-8.
01.01.2008Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
01.01.2008The Lancet 2008; 9:23-8
Rasmussen Birgitte B, Altermatt Hans J, Gelber Richard D, Castiglione-Gertsch Monica, Goldhirsch Aron, Gusterson Barry A, Thürlimann Beat, Coates Alan S, Viale Giuseppe, Braye Stephen, Lacroix-Triki Magali, Regan Meredith M, Lykkesfeldt Anne E, Dell'Orto Patrizia, Del Curto Barbara, Henriksen Katrine L, Mastropasqua Mauro G, Price Karen N, Méry Eliane, BIG 1-98 Collaborative and International Breast Cancer Study Groups